Hint mode is switched on Switch off

Ardelyx, ordinary share
ARDX, US0396971071

Add a stock to WL
Choose all Reset all
Ardelyx, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

  • Issuer
  • Full borrower / issuer name
    Ardelyx, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ARDX
  • Placement
    19.06.2014
  • Lock up period
    180
  • Number of papers
    4,286,000
  • Volume of raised funds
    60 mln USD
  • Final placement price
    14 USD
  • Price change since placement date
    -60.43%
  • By capitalization
    250.41 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ARDX
  • Placement
    08.01.2016
  • Lock up period
    180
  • Number of papers
    7,500,000
  • Volume of raised funds
    75 mln USD
  • Placement share
    22.42%
  • Final placement price
    10 USD
  • Price change since placement date
    -44.6%
  • By capitalization
    334.55 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ARDX
  • Placement
    05.12.2019
  • Lock up period
    180
  • Number of papers
    20,000,000
  • Volume of raised funds
    125 mln USD
  • Placement share
    24.13%
  • Final placement price
    6.25 USD
  • Price change since placement date
    -11.36%
  • By capitalization
    518.02 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide

Related Stock indices

Indicators

News

19/02/2026 Ardelyx: , Including Exhibit 99.1 Hereto, Shall Not Be Considered “filed” Under The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Nor Shall It Be Incorporated By Reference Into Any Future Filing Under The Securities Act Of 1933, As Amended (the “securities Act”), Or Underthe Exchange Act, Unless The Company Expressly Sets Forth In Such Future Filing That Such Information Is To Be Considered “filed” Or Incorporated By Reference Therein, Regulation Fd Disclosure, Financial Statements And Exhibits
09/01/2026 Ardelyx, Inc. (NASDAQ:ARDX) Receives "Strong Buy" Rating from Raymond James
08/01/2026 Ardelyx: Is Incorporated Into This Item 8.01 By Reference, Financial Statements And Exhibits
03/01/2026 Raymond James Reaffirms Strong Buy on Ardelyx After Drug Price Increases
01/08/2025 Ardelyx: Shall Not Be Considered “filed” Under The Securities Exchange Act Of 1934, As Amended, Nor Shall It Be Incorporated By Reference Into Any Future Filing Under The Securities Act Of 1933, As Amended, Or Underthe Securities Exchange Act Of 1934, As Amended, Unless The Company Expressly Sets Forth In Such Future Filing That Such Information Is To Be Considered “filed” Or Incorporated By Reference Therein, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.